Published in J Immunol on August 15, 2007
Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol (2010) 4.92
The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One (2008) 4.52
The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A (2009) 3.39
Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev (2008) 3.33
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov (2008) 2.90
Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood (2008) 2.88
IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci U S A (2009) 2.83
Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med (2010) 2.38
The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol (2011) 2.33
IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A (2007) 2.27
Role of IL-33 in inflammation and disease. J Inflamm (Lond) (2011) 2.06
Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res (2010) 1.80
Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol (2008) 1.76
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity (2013) 1.67
IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci U S A (2008) 1.67
Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol (2008) 1.59
IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One (2010) 1.54
Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol (2012) 1.52
Regulation of mast cell responses in health and disease. Crit Rev Immunol (2011) 1.50
Danger signals activating the immune response after trauma. Mediators Inflamm (2012) 1.40
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood (2012) 1.36
Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med (2009) 1.36
IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol (2011) 1.32
IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res (2009) 1.27
Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure (2009) 1.24
Lineage(-)Sca1+c-Kit(-)CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow. J Immunol (2011) 1.22
Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol (2012) 1.22
The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol (2009) 1.19
IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc Natl Acad Sci U S A (2012) 1.19
The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood (2015) 1.18
Dynamic role of epithelium-derived cytokines in asthma. Clin Immunol (2012) 1.14
A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1. Immunity (2009) 1.14
The β-glucan receptor dectin-1 promotes lung immunopathology during fungal allergy via IL-22. J Immunol (2012) 1.13
Interleukin-33 in asthma: how big of a role does it play? Curr Allergy Asthma Rep (2011) 1.13
New Insights in the Immunobiology of IL-1 Family Members. Front Immunol (2013) 1.12
Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair (2012) 1.11
Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. Front Immunol (2013) 1.11
Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One (2013) 1.10
In silico identification of plant miRNAs in mammalian breast milk exosomes--a small step forward? PLoS One (2014) 1.09
IL-33 mediates multi-walled carbon nanotube (MWCNT)-induced airway hyper-reactivity via the mobilization of innate helper cells in the lung. Nanotoxicology (2012) 1.09
Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A (2013) 1.09
Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol (2013) 1.08
IL-1 family cytokines trigger sterile inflammatory disease. Front Immunol (2012) 1.07
Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci (2011) 1.07
Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol (2016) 1.04
Expression and regulation of interleukin-33 in human monocytes. Immunology (2010) 1.04
Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol (2011) 1.03
IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun (2014) 1.03
Defining the subcellular sites of innate immune signal transduction. Trends Immunol (2012) 1.02
Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Current knowledge assembled at an international workshop at BfR, Germany. Cell Mol Life Sci (2011) 1.02
Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B. J Interferon Cytokine Res (2012) 1.01
Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol (2014) 1.00
An Interleukin-33-Mast Cell-Interleukin-2 Axis Suppresses Papain-Induced Allergic Inflammation by Promoting Regulatory T Cell Numbers. Immunity (2015) 0.98
Neonatal sepsis and inflammatory mediators. Mediators Inflamm (2014) 0.98
Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol (2013) 0.98
VASCULAR INFLAMMATION AND ATHEROGENESIS ARE ACTIVATED VIA RECEPTORS FOR PAMPs AND SUPPRESSED BY REGULATORY T CELLS. Drug Discov Today Ther Strateg (2008) 0.98
IL-33 is induced by amyloid-β stimulation and regulates inflammatory cytokine production in retinal pigment epithelium cells. Inflammation (2012) 0.94
Identification of constitutively active interleukin 33 (IL-33) splice variant. J Biol Chem (2011) 0.94
Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell Mol Life Sci (2010) 0.94
Paracrine IL-33 stimulation enhances lipopolysaccharide-mediated macrophage activation. PLoS One (2011) 0.93
The E3 ubiquitin ligase MARCH8 negatively regulates IL-1β-induced NF-κB activation by targeting the IL1RAP coreceptor for ubiquitination and degradation. Proc Natl Acad Sci U S A (2012) 0.92
The role of IL-33 and mast cells in allergy and inflammation. Clin Transl Allergy (2015) 0.91
Mast Cells Respond to Cell Injury through the Recognition of IL-33. Front Immunol (2012) 0.91
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun (2015) 0.90
IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci U S A (2015) 0.90
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol (2016) 0.89
Hypoxia-inducible factor-1α and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis. PLoS One (2013) 0.89
Implications for Interleukin-33 in solid organ transplantation. Cytokine (2013) 0.89
Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models. PLoS One (2014) 0.88
Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol (2014) 0.88
Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. J Neuroimmune Pharmacol (2013) 0.88
Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity. J Biol Chem (2012) 0.88
Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice. Immunology (2013) 0.87
IL-33 attenuates the development of experimental autoimmune uveitis. Eur J Immunol (2014) 0.87
Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma. Mediators Inflamm (2010) 0.87
Inducible IL-33 expression by mast cells is regulated by a calcium-dependent pathway. J Immunol (2012) 0.84
The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep (2013) 0.83
Immunology: The expanding T(H)2 universe. Nature (2010) 0.83
The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin Immunopathol (2016) 0.83
Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine (2012) 0.82
Structural biology of the IL-1 superfamily: key cytokines in the regulation of immune and inflammatory responses. Protein Sci (2014) 0.81
The role of IL-33 in rheumatic diseases. Clin Dev Immunol (2013) 0.80
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis. Ann Clin Transl Neurol (2014) 0.80
The physiopathological role of IL-33: new highlights in bone biology and a proposed role in periodontal disease. Mediators Inflamm (2014) 0.80
The ST2 pathway is involved in acute pancreatitis: a translational study in humans and mice. Am J Pathol (2012) 0.80
The IL-33 gene is related to increased susceptibility to systemic sclerosis. Rheumatol Int (2016) 0.79
Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. Biomed Res Int (2014) 0.79
Evidence of perturbations of the cytokine network in preterm labor. Am J Obstet Gynecol (2015) 0.79
Serum amyloid A induces interleukin-33 expression through an IRF7-dependent pathway. Eur J Immunol (2014) 0.79
The GOLD domain-containing protein TMED1 is involved in interleukin-33 signaling. J Biol Chem (2013) 0.79
Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol (2016) 0.78
Red Blood Cells Store and Release Interleukin-33. J Investig Med (2015) 0.78
IFN-γ directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism. J Biol Chem (2014) 0.78
Associations between variants in IL-33/ST2 signaling pathway genes and coronary heart disease risk. Int J Mol Sci (2014) 0.77
Recombinant IL-33 prolongs leflunomide-mediated graft survival by reducing IFN-γ and expanding CD4(+)Foxp3(+) T cells in concordant heart transplantation. Lab Invest (2016) 0.77
Deconstructing innate immune signaling in myelodysplastic syndromes. Exp Hematol (2015) 0.76
Functional interleukin-33 receptors are expressed in early progenitor stages of allergy-related granulocytes. Immunology (2016) 0.76
Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12. Immunobiology (2015) 0.76
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol (2007) 12.76
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest (2006) 11.89
Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol (2002) 10.15
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol (2002) 9.30
IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity (2002) 8.19
Understanding the IL-23-IL-17 immune pathway. Trends Immunol (2005) 6.79
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity (2003) 5.60
The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity (2003) 5.11
IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature (2010) 5.07
IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev (2004) 4.78
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest (2006) 4.77
IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol (2007) 4.54
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med (2012) 4.38
Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology (2007) 3.82
IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med (2007) 3.69
WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol (2004) 3.55
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med (2006) 3.38
Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med (2006) 3.36
Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med (2009) 2.82
Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J Exp Med (2008) 2.63
Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med (2009) 2.41
Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med (2008) 2.41
IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol (2009) 2.39
IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J Immunol (2004) 2.37
IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res (2003) 2.08
IL-27 limits IL-2 production during Th1 differentiation. J Immunol (2006) 1.89
Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol (2007) 1.77
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
Therapeutic targeting of Syk in autoimmune diabetes. J Immunol (2010) 1.69
IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol (2006) 1.68
Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity (2013) 1.67
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol (2003) 1.56
Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol (2003) 1.55
Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol (2008) 1.50
SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem (2002) 1.48
IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol (2009) 1.42
Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol (2011) 1.35
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother (2007) 1.30
TGF-beta, a 'double agent' in the immune pathology war. Nat Immunol (2006) 1.27
Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol (2004) 1.25
The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol (2009) 1.19
Differential effects of IL-27 on human B cell subsets. J Immunol (2006) 1.18
Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun (2006) 1.17
Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol (2005) 1.13
Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis. J Exp Med (2010) 1.13
Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J Biol Chem (2004) 1.09
The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem J (2004) 0.98
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2011) 0.97
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int (2010) 0.96
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother (2009) 0.96
Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford) (2009) 0.93
Identification of CLEC12B, an inhibitory receptor on myeloid cells. J Biol Chem (2007) 0.93
Syk inhibitors as treatment for allergic rhinitis. Pulm Pharmacol Ther (2007) 0.92
Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease. Clin Transl Gastroenterol (2012) 0.92
Borrelia burgdorferi potently activates bone marrow-derived conventional dendritic cells for production of IL-23 required for IL-17 release by T cells. FEMS Immunol Med Microbiol (2007) 0.91
Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther (2013) 0.89
Average probability that a "cold hit" in a DNA database search results in an erroneous attribution. J Forensic Sci (2008) 0.88
Administration of IL-23 engages innate and adaptive immune mechanisms during fungal infection. Int Immunol (2009) 0.87
The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging (2010) 0.87
Type A intradural spinal arteriovenous fistula. Case report. J Neurosurg Spine (2006) 0.86
Glycosylation analysis of interleukin-23 receptor: elucidation of glycosylation sites and characterization of attached glycan structures. J Mass Spectrom (2010) 0.85
The emerging role of Interleukin 27 in inflammatory arthritis and bone destruction. Cytokine Growth Factor Rev (2012) 0.83
C17 prevents inflammatory arthritis and associated joint destruction in mice. PLoS One (2011) 0.81
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C. Antivir Ther (2014) 0.79
Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells. MAbs (2009) 0.76
MTH1 and RGT1 demonstrate combined haploinsufficiency in regulation of the hexose transporter genes in Saccharomyces cerevisiae. BMC Genet (2012) 0.75
A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex. Mol Immunol (2006) 0.75